Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors.
about
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsOptimized approaches for quantification of drug transporters in tissues and cells by MRM proteomicsPrediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability.Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionPrediction of hepatic clearance in human from in vitro data for successful drug development.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Maraviroc: in vitro assessment of drug-drug interaction potentialThe role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.Cytochrome P450 reaction-phenotyping: an industrial perspective.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.Human clearance prediction: shifting the paradigm.Knowledge-driven approaches for the guidance of first-in-children dosing.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.Reaction phenotyping to assess victim drug-drug interaction risks.A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity.Application of PBPK modelling in drug discovery and development at Pfizer.Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors.Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.Mechanistic models describing active renal reabsorption and secretion: a simulation-based study.
P2860
Q26764739-6B5B9614-ACB3-472B-8AC9-D5775CDE73BBQ26851693-377CB07E-3A05-467D-9B5C-7A71078C81F4Q31044030-BDC75289-049E-4ED9-B30A-62FF78F0556DQ31146882-A86DF51D-7C43-4ABB-A21C-74DB35F09186Q33437736-931E8851-8641-4CB2-B049-92C7F85E21B9Q34503553-FDA5AF05-BBCE-419C-BDCE-1D8E684297AEQ34561039-78519954-9766-48FA-B4E8-1B32AB79A49EQ34594626-C26C61DC-160D-4AE9-A123-05D437BDC9F6Q35560052-99F2C2DA-ADCD-4A5F-9FA4-6F76EB62B1B1Q36123295-2336337F-9111-40DA-A9F7-15A160492B30Q36335446-E6FC0802-21F7-48C0-A5EA-3F55FFECB09EQ36702463-C7722C1E-C017-4C3C-883D-944A9CFCD08DQ36960539-51C967D9-456A-4EBE-8EA5-8579AD9FF144Q37008900-37619AE1-F313-4259-850B-A789FE162FCEQ37150887-021B0757-9658-4242-916A-6F233DFABA93Q37279044-C9CECD9C-60CE-425F-9522-614DBA99412DQ37325589-B775882F-91D8-4C13-9982-34C7F7819E14Q37554400-116D904B-691C-4B82-86BC-1C3026B68D15Q37815555-186293F8-7CEC-4989-A2C7-89DE1B44AF7BQ37960638-08A5797D-6828-4B10-A395-48785C827CC4Q37965706-81E5F655-D097-46D9-AD95-42A3D59F1F05Q38014312-DAD30811-2F0D-4CD9-803E-E257EEAD9644Q38016204-2F9086BC-D412-4A0A-805C-C44AD168D60AQ38038547-BB0EF286-BBC9-43C4-9ED8-95E4B1E7D670Q38087695-FCDDBFC3-C9D5-4DB6-BF87-E4AF75908C21Q38089823-2AED380A-C957-420E-8187-0881BDE285C4Q38640403-27617E3A-F56E-4BAE-AC03-3313E5A601BBQ38661092-ADC25F97-E07C-4C38-BF21-2171EC680724Q38798449-14E15AA1-7D58-4889-B421-04835DB8E78DQ39642897-3E9A70E3-ED08-477B-AD3F-AE7BA207A20AQ39692575-DB412E9C-7478-4579-8FDE-38900E74CAC7Q39732707-CA110336-62C2-44AB-B1D3-6A069D1EF170Q39773047-6B0D8478-773C-4CC4-AADA-6246C82CD44AQ39989580-16A732AB-124D-4F2B-86A7-B474D73616CBQ40282075-7FBCECDF-3169-477E-AE41-0995F6B80582Q40568343-5B133308-9FC6-4373-8007-E97B2974B93FQ40991626-3943BC14-6356-4CFE-8103-52F0C71B2F43Q41118521-6D87F24D-ADA0-49AD-AB29-DBC83CAF36D6Q41582110-3101C073-00DB-4292-AE46-0E1744707F44Q41986968-536B3AE5-7991-415A-BD55-965BD0854804
P2860
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Predicting drug clearance from ...... rsystem extrapolation factors.
@en
type
label
Predicting drug clearance from ...... rsystem extrapolation factors.
@en
prefLabel
Predicting drug clearance from ...... rsystem extrapolation factors.
@en
P2093
P2860
P1433
P1476
Predicting drug clearance from ...... rsystem extrapolation factors.
@en
P2093
Proctor NJ
Rostami-Hodjegan A
P2860
P304
P356
10.1080/00498250310001646353
P407
P577
2004-02-01T00:00:00Z